UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 146

Sortiert nach

Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial

The Lancet (British edition), 2011, Vol.377 (9776), p.1506-1513

2011

Volltextzugriff (PDF)

Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia

Schizophrenia research, 2017-01, Vol.179, p.64-69

2017

Volltextzugriff (PDF)

Antagonist Treatment for Opioid Use Disorder

The American journal of medicine, 2017-03, Vol.130 (3), p.e117-e117

2017

Volltextzugriff (PDF)

Acanthosis Nigricans Identifies Youth at High Risk for Metabolic Abnormalities

The Journal of pediatrics, 2010, Vol.156 (1), p.87-92

2010

Volltextzugriff (PDF)

Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia

The American journal of psychiatry, 2019-06, Vol.176 (6), p.457-467

2019

Volltextzugriff (PDF)

A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia

The journal of clinical psychiatry, 2015-08, Vol.76 (8), p.1085

2015

Volltextzugriff (PDF)

A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers

Schizophrenia research, 2018-05, Vol.195, p.245-251

2018

Volltextzugriff (PDF)

A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension

Schizophrenia research, 2021-06, Vol.232, p.45-53

2021

Volltextzugriff (PDF)

Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness

Addiction (Abingdon, England), 2013-09, Vol.108 (9), p.1628-1637

2013

Volltextzugriff (PDF)

Impaired glucose tolerance in adolescent offspring of diabetic mothers. Relationship to fetal hyperinsulinism

Diabetes care, 1995-05, Vol.18 (5), p.611

1995

Volltextzugriff (PDF)

Opioid use and dropout from extended‐release naltrexone in a controlled trial: implications for mechanism

Addiction (Abingdon, England), 2020-02, Vol.115 (2), p.239-246

2020

Volltextzugriff (PDF)

Effects of the Opioid System Modulator, Samidorphan, on Measures of Alcohol Consumption and Patient‐Reported Outcomes in Adults with Alcohol Dependence

Alcoholism, clinical and experimental research, 2018-10, Vol.42 (10), p.2011-2021

2018

Volltextzugriff (PDF)

Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers

Neuropsychopharmacology (New York, N.Y.), 2022-02, Vol.47 (3), p.696-703

2022

Volltextzugriff (PDF)

Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial

Drug and alcohol dependence, 2018-06, Vol.187, p.171-178

2018

Volltextzugriff (PDF)

Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia

The journal of clinical psychiatry, 2016-11, Vol.77 (11), p.1519

2016

Volltextzugriff (PDF)

Reply to Kunoe (2020) and Ghosh & Singh (2020) regarding Nunes et al. (2020): Opioid use and dropout from extended‐release naltrexone in a controlled trial: implications for mechanism

Addiction (Abingdon, England), 2020-11, Vol.115 (11), p.2188-2190

2020

Volltextzugriff (PDF)

Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial

JAMA : the journal of the American Medical Association, 2005-04, Vol.293 (13), p.1617

2005

Volltextzugriff (PDF)

A Combination of Olanzapine and Samidorphan in Adults with Schizophrenia and Bipolar I Disorder: Overview of Clinical Data

CNS spectrums, 2021-04, Vol.26 (2), p.170-170

2021

Volltextzugriff (PDF)

Extended‐release naltrexone (XR‐NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry

Addiction (Abingdon, England), 2018-08, Vol.113 (8), p.1477-1487

2018

Volltextzugriff (PDF)

Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended‐Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens

The American journal on addictions, 2020-07, Vol.29 (4), p.313-322

2020

Volltextzugriff (PDF)

Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale—supportive analyses from a Phase 3 study

CNS spectrums, 2018-08, Vol.23 (4), p.284-290

2018

Volltextzugriff (PDF)

Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia

International clinical psychopharmacology, 2016-03, Vol.31 (2), p.69

2016

Volltextzugriff (PDF)

A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder

The International journal of eating disorders, 2013-04, Vol.46 (3), p.239-245

2013

Volltextzugriff (PDF)

26 A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Patients with Acute Exacerbation of Schizophrenia

CNS spectrums, 2019-02, Vol.24 (1), p.187-188

2019

Volltextzugriff (PDF)

Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection

Journal of studies on alcohol and drugs, 2012-11, Vol.73 (6), p.991-997

2012

Volltextzugriff (PDF)

1 – 25 von 146

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(136)
Mit Volltextzugriff
(120)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(105)
Life Sciences & Biomedicine
(99)
Humans
(89)
Female
(65)
Male
(64)
Biological And Medical Sciences
(47)
Medical Sciences
(42)
Adult
(39)
Middle Aged
(37)
Child
(22)
Psychiatry
(22)
Treatment Outcome
(21)
Aged
(19)
Double-Blind Method
(19)
Adolescent
(18)
Pediatrics
(16)
Delayed-Action Preparations
(15)
Child, Preschool
(14)
General & Internal Medicine
(14)
Naltrexone - Administration & Dosage
(14)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial

Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia

Antagonist Treatment for Opioid Use Disorder

Acanthosis Nigricans Identifies Youth at High Risk for Metabolic Abnormalities

Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia

A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia

A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers

A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension

Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness

Impaired glucose tolerance in adolescent offspring of diabetic mothers. Relationship to fetal hyperinsulinism

Opioid use and dropout from extended‐release naltrexone in a controlled trial: implications for mechanism

Effects of the Opioid System Modulator, Samidorphan, on Measures of Alcohol Consumption and Patient‐Reported Outcomes in Adults with Alcohol Dependence

Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers

Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial

Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia

Reply to Kunoe (2020) and Ghosh & Singh (2020) regarding Nunes et al. (2020): Opioid use and dropout from extended‐release naltrexone in a controlled trial: implications for mechanism

Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial

A Combination of Olanzapine and Samidorphan in Adults with Schizophrenia and Bipolar I Disorder: Overview of Clinical Data

Extended‐release naltrexone (XR‐NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry

Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended‐Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens

Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale—supportive analyses from a Phase 3 study

Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia

A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder

26 A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Patients with Acute Exacerbation of Schizophrenia

Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection

Suchergebnisse filtern